AbbVie receives approval from NICE for Tepkinly
AbbVie's Tepkinly has been recommended by NICE as a treatment option for eligible adults with diffuse large B-cell lymphoma
AbbVie recently shared that the United Kingdom's National Institute for Health and Care Excellence (NICE) has given their recommendation for Tepkinly (epcoritamab) as a potential treatment for eligible adults diagnosed with diffuse large B-cell lymphoma (DLBCL).
The suggestion, derived from a study involving a single-arm Phase I/II clinical trial, is to consider the use of subcutaneous therapy in adults diagnosed with DLBCL who have experienced either relapse or inadequate response to multiple lines of systemic therapy. Epcoritamab is a bispecific antibody that has been developed to bind to both immune T cells and cancerous lymphoma cells at the same time. When the bispecific antibody brings the immune T cell and the cancerous cell together, the T cell becomes activated and proceeds to destroy the cancerous cell.
DLBCL is a form of blood cancer that, although most individuals achieve remission with standard treatment, there is a possibility of cancer recurrence for some. People with relapsed or refractory DLBCL often feel anxious about the possibility of not responding to treatment or the cancer coming back, according to a policy officer at Blood Cancer UK, as stated in the press release. Epcoritamab (Tepkinly) is an injectable bispecific antibody that has been developed to facilitate the recognition and attachment of cancer cells and immune cells. This enables the body's immune system to effectively eliminate these harmful cells. The approval of epcoritamab by NICE for eligible patients on the NHS in England and Wales is a positive development that will be appreciated by many.
Despite recent therapeutic advances, the available treatment options for this challenging group of patients have been quite limited. This can lead to a lack of effective treatment options for many patients, which unfortunately results in a poor prognosis. Physicians now have another treatment option available for eligible patients with relapsed or refractory diffuse large B cell lymphoma after multiple lines of therapy, thanks to NICE's decision on epcoritamab.
Source: AbbVie
